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ABSTRACT
Objectives To assess the diagnostic accuracy of placental
growth factor (PlGF) and ultrasound parameters to pre-
dict delivery of a small-for-gestational-age (SGA) infant in
women presenting with reduced symphysis–fundus height
(SFH).
Methods This was a multicenter prospective observa-
tional study recruiting 601 women with a singleton
pregnancy and reduced SFH between 24 and 37 weeks’
gestation across 11 sites in the UK and Canada. Plasma
PlGF concentration <5th centile, estimated fetal weight
(EFW) < 10th centile, umbilical artery Doppler pulsatility
index> 95th centile and oligohydramnios (amniotic fluid
index< 5 cm) were compared as predictors for a SGA
infant< 3rd customized birth-weight centile and adverse
perinatal outcome. Test performance statistics were calcu-
lated for all parameters in isolation and in combination.
Results Of the 601 women recruited, 592 were analyzed.
For predicting delivery of SGA< 3rd centile (n = 78),
EFW< 10th centile had 58% sensitivity (95% CI,
46–69%) and 93% negative predictive value (NPV)
(95% CI, 90–95%), PlGF had 37% sensitivity (95% CI,
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27–49%) and 90% NPV (95% CI, 87–93%); in com-
bination, PlGF and EFW< 10th centile had 69% sen-
sitivity (95% CI, 55–81%) and 93% NPV (95% CI,
89–96%). The equivalent receiver–operating character-
istics (ROC) curve areas were 0.79 (95% CI, 0.74–0.84)
for EFW< 10th centile, 0.70 (95% CI, 0.63–0.77) for low
PlGF and 0.82 (95% CI, 0.77–0.86) in combination.
Conclusions For women presenting with reduced SFH,
ultrasound parameters had modest test performance for
predicting delivery of SGA < 3rd centile. PlGF performed
no better than EFW< 10th centile in determining delivery
of a SGA infant. © 2015 The Authors. Ultrasound
in Obstetrics & Gynecology published by John Wiley
& Sons Ltd on behalf of the International Society of
Ultrasound in Obstetrics and Gynecology.
INTRODUCTION
Fetal growth restriction (FGR) is a failure to fulfill growth
potential, associated with an increased risk of stillbirth1,
neonatal morbidity2,3 and mortality4–7. Complications
can extend into adult life, with a greater risk of
cardiovascular disease and Type 2 diabetes mellitus8.
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd ORIGINAL PAPER
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Small-for-gestational-age (SGA) infants are defined
typically as those with a birth weight <3rd, < 5th or
< 10th centile; these include constitutionally small infants
and those with FGR and, as a group, these pregnancies
are at increased risk of adverse neonatal outcome9.
Identifying SGA infants remains challenging in the
low-risk population, relying on imprecise techniques such
as symphysis–fundus height (SFH) measurement10. If
SGA is suspected, UK national guidance recommends
ultrasound measurements of abdominal circumference
(AC) or estimated fetal weight (EFW)< 10th centile to
diagnose SGA11,12. However, a large proportion of SGA
infants are not detected antenatally (32% of 215 high-risk
women1 and 82% of 195 stillbirths with SGA13).
UK national guidance11 does not advocate routine
ultrasound measurement in the third trimester as a
screening tool for SGA owing to poor prediction
(sensitivity, 38–51%)14–17 and no evidence of improved
neonatal outcome18. However, preliminary results from a
recent large prospective cohort study reported increased
sensitivity of screening (79%) vs selective (32%)
sonography in the third trimester for prediction of severe
SGA in an unselected nulliparous population19.
Whilst the pathophysiology of FGR is multifactorial,
placental insufficiency is causative in many cases. Markers
of placental function could provide adjuncts to current
techniques to identify high-risk pregnancies. Multiple
biomarkers have been proposed to aid detection but
none has sufficient accuracy for incorporation into
clinical practice20. However, low levels of maternal serum
placental growth factor (PlGF) can distinguish placental
SGA from constitutionally small fetuses (sensitivity,
100%; specificity, 86%)21 and, in a high-risk cohort with
suspected preterm pre-eclampsia (PE), can predict PE and
delivery of a SGA infant (birth weight< 1st centile) with
high sensitivity22.
We performed a large prospective multicenter cohort
study in women with suspected SGA (reduced SFH
measurement) with the aim of assessing the diagnostic
accuracy of PlGF levels and ultrasound parameters to
predict delivery of a SGA infant.
METHODS
Women were enrolled from 11 consultant-led units across
the UK and Canada, between December 2011 and July
2013 (approximate number of deliveries per year: St
Thomas’ Hospital London, 6650; St Mary’s Hospital
Manchester, 8200; Oxford, 6550; Leeds, 9550; Sheffield,
7000; St George’s Hospital London, 4950; St Michael’s
Hospital Bristol, 5500; Lewisham, 4000; West Middlesex
Hospital, 4700; Sunderland, 3200; Vancouver, 7000).
Local audit data at St Thomas’ Hospital London in the
year prior to study commencement (2011) showed that
approximately 1300 women were referred with reduced
SFH. Of these women, 8% delivered an SGA infant with
customized birth weight< 3rd centile for gestational age.
Ethical approval was granted by East London Research
Ethics Committee (ref. 10/H0701/117).
Women were eligible if they were ≥ 16 years of age, with
a singleton pregnancy between 24 + 0 and 36 + 6 weeks’
gestation and referred for suspected SGA because of
either: (i) a SFH measuring> 2 cm less than the expected
height for any given gestational age in completed weeks
(e.g. measuring ≤ 33 cm at 36 weeks’ gestation); or (ii) a
SFH< 10th centile on a customized SFH chart. Women
with SGA confirmed already (EFW< 10th customized
centile), a major fetal anomaly (fetal malformations that
affect viability and/or quality of life of the fetus and
require intervention23) or confirmed rupture of amniotic
membranes were excluded.
Written informed consent was obtained from par-
ticipants. A study-specific database was designed and
finalized before recruitment of the first participant. On
the same day as the ultrasound scan, baseline demo-
graphic and pregnancy-specific data were entered into the
database and PlGF testing was performed. Blood was
drawn into ethylenediamine tetra-acetic acid and labeled
with a study-specific coded identifier. Samples were trans-
ported to the laboratory at the recruiting site and spun
for 10 min at 1400 g. Plasma was extracted from each
sample and stored at −80 ◦C until required for analy-
sis. All samples were analyzed for PlGF at the recruiting
site using the AlereTriage®PLGF (Alere, San Diego, CA,
USA) test, according to the manufacturer’s instructions.
All laboratory staff received standardized training in sam-
ple processing, delivered by the study monitor. All meters
were programmed to produce a blinded result, determin-
ing satisfactory test completion only, without revealing the
value. All laboratory staff were blinded to the clinical diag-
nosis. The assay uses fluorescently labeled recombinant
murine monoclonal antibodies and detects PlGF specifi-
cally and quantitatively, in the range of 12–3000 pg/mL,
in approximately 15 min. The lower limit of detection
of the assay is 12 pg/mL and PlGF results were classi-
fied as normal (PlGF ≥ 5th centile for gestational age),
low (< 5th centile) and very low (< 12 pg/mL). To deter-
mine assay reproducibility, replicate samples were also
tested at a central laboratory. The total precision (coeffi-
cient of variation) on plasma controls, at concentrations
of 85 pg/mL and 1300 pg/mL, was 12.8% and 13.2%,
respectively.
All case outcomes were adjudicated by two independent
senior physicians, without knowledge of PlGF concentra-
tions. SGA was defined as delivery of an infant with
a birth weight< 3rd (or< 10th as a secondary analy-
sis) customized birth-weight centile, calculated using the
Gestation Related Optimal Weight (GROW) method
software24. A final maternal diagnosis was assigned using
definitions from the American College of Obstetricians
and Gynecologists’ practice bulletin for maternal hyper-
tensive disorders25 and the International and Australasian
Societies for the Study of Hypertension in Pregnancy for
atypical PE, as predefined in the study protocol26.
Any hospital attendances subsequent to enrolment
were recorded in the study database, including repeat
ultrasound assessments, details of delivery and adverse
maternal and perinatal outcomes. Adverse maternal
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2015; 46: 182–190.
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Total recruited (n = 601)
Excluded:
 No PlGF result (n = 5):
  No plasma sample for analysis (n = 2)
  Sample labeled incorrectly (n = 3)
 No outcome data (n = 2)
 No ultrasound scan data at enrollment (n = 2)
Total for analysis (n = 592)
PlGF ≥ 5th centile (n = 505)PlGF < 5th centile (n = 87)
SGA < 3rd centile
(n = 29)
SGA < 3rd centile
(n = 49)
BW ≥ 3rd centile
(n = 58)
BW ≥ 3rd centile
(n = 456)
Figure 1 Flowchart of study population of women with singleton pregnancy presenting with reduced symphysis–fundus height. BW, birth
weight; PlGF, placental growth factor; SGA, small-for-gestational age.
Table 1 Maternal characteristics of 592 women with singleton pregnancy and reduced symphysis–fundus height at booking, according to
subsequent birth-weight (BW) centile of infant
Characteristic
SGA<3rd centile
(n = 78)
SGA< 10th centile
(n = 192)
BW ≥ 10th centile
(n = 400)
All women
(n = 592)
Maternal age (years) 29.1 (24.1–32.9) 29.6 (24.8–33.5) 30.0 (25.3–33.7) 29.9 (25.2–33.6)
BMI (kg/m2) 22.9 (20.3–25.2) 21.7 (20.1–24.1) 21.5 (20.0–23.4) 21.5 (20.0–23.6)
White ethnicity 52 (66.7) 122 (63.5) 266 (66.5) 388 (65.5)
Nulliparous 65 (83.3) 163 (84.9) 344 (86.0) 507 (85.6)
Highest first-trimester systolic BP (mmHg) 105 (100–114) 105 (100–114) 104 (100–112) 105 (100–112)
Highest first-trimester diastolic BP (mmHg) 63 (60–70) 62 (60–70) 60 (60–69) 61 (60–70)
Smoking status
Never smoked 46 (59.0) 128 (66.7) 306 (76.5) 434 (73.3)
Quit smoking before pregnancy 9 (11.5) 22 (11.5) 31 (7.8) 53 (8.9)
Quit smoking during pregnancy 10 (12.8) 16 (8.3) 24 (6.0) 40 (6.7)
Current smoker 13 (16.7) 26 (13.5) 39 (9.8) 65 (11.0)
Drug use
History of drug use* 5 (6.4) 6 (3.1) 3 (0.8) 9 (1.5)
Current drug user† 1 (1.3) 2 (1.0) 0 (0) 2 (0.3)
Medical history
PE requiring delivery at< 34 weeks 0 (0) 0 (0) 1 (0.3) 1 (0.2)
Chronic hypertension 0 (0) 1 (0.5) 1 (0.3) 2 (0.3)
SLE/APS 1 (1.3) 1 (0.5) 0 (0) 1 (0.2)
Pre-existing diabetes mellitus 0 (0) 0 (0) 1 (0.3) 1 (0.2)
Renal disease 0 (0) 0 (0) 0 (0) 0 (0)
Self-report of previous small baby 9 (11.5) 22 (11.5) 27 (6.8) 49 (8.3)
Data are given as median (interquartile range) or n (%). *Including cannabis, cocaine, ecstasy, amphetamines (speed and/or crystal meth)
and heroin. †Cannabis only (rare or occasional use). APS, antiphospholipid syndrome; BMI, body mass index; BP, blood pressure; PE,
pre-eclampsia; SGA, small-for-gestational age; SLE, systemic lupus erythematosus.
outcome was predefined as the presence of any of
the following complications: maternal death; eclamp-
sia; stroke; cortical blindness or retinal detachment;
hypertensive encephalopathy; systolic blood pres-
sure ≥ 160 mmHg; myocardial infarction; intubation
(other than for Cesarean section); pulmonary edema;
platelet count< 50 × 109/L (without transfusion);
disseminated intravascular coagulation; thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome;
hepatic dysfunction (alanine transaminase ≥ 70 IU/L);
hepatic hematoma or rupture; acute fatty liver of
pregnancy; creatinine>150 μmol/L; renal dialysis;
placental abruption; major postpartum hemorrhage; or
major infection. Adverse perinatal outcome was defined
as the presence of any of the following complications:
antepartum/intrapartum fetal or neonatal death; neonatal
unit admission for> 48 h following term delivery; intra-
ventricular hemorrhage; periventricular leukomalacia;
seizure; retinopathy of prematurity; respiratory distress
syndrome; bronchopulmonary dysplasia; or necrotizing
enterocolitis. An independent observer conducted regular
data monitoring at all sites.
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2015; 46: 182–190.
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Table 2 Baseline characteristics of 592 women with singleton pregnancy presenting with reduced symphysis–fundus height at study
enrolment, according to birth-weight (BW) centile of infant
Characteristic
SGA<3rd centile
(n = 78)
SGA< 10th centile
(n = 192)
BW ≥ 10th centile
(n = 400)
All women
(n = 592)
Gestational age (days) 238 (221–250) 235 (213–250) 236 (214–250) 236 (213–250)
Maternal BP
Highest systolic BP (mmHg) 118 (109–129) 115 (102–121) 110 (101–118) 110 (101–120)
Highest diastolic BP (mmHg) 70 (60–81) 70 (60–80) 67 (60–73) 68 (60–74)
Dipstick proteinuria
Not done 11 (14.1) 29 (15.1) 61 (15.3) 90 (15.2)
Negative 58 (74.4) 148 (77.1) 322 (80.5) 470 (79.4)
Positive* 9 (11.5) 15 (7.8) 17 (4.3) 32 (5.4)
Complications in current pregnancy
Gestational hypertension 4 (5.1) 4 (2.1) 0 (0) 4 (0.7)
Pre-eclampsia 0 (0) 1 (0.5) 1 (0.3) 2 (0.3)
Gestational diabetes 1 (1.3) 3 (1.5) 4 (1.0) 7 (1.2)
Intrahepatic cholestasis of pregnancy 0 (0.0) 1 (0.5) 2 (0.5) 3 (0.5)
Fetal characteristics
EFW< 10th centile 44 (57.9) 88 (47.1) 64 (16.3) 152 (25.9)
Oligohydramnios (AFI< 5 cm) 2 (3.6) (n = 54) 4 (3.3) (n = 118) 1 (0.4) (n = 228) 5 (1.4) (n = 346)
Absent/reversed UA flow 1 (1.3) (n = 76) 1 (0.6) (n = 176) 1 (0.3) (n = 358) 2 (0.4) (n = 534)
UA-PI > 95th centile 10 (16.1) (n = 61) 12 (8.2) (n = 147) 14 (4.5) (n = 312) 26 (5.7) (n = 458)
Data are given as median (interquartile range) or n (%). *+1 or greater. AFI, amniotic fluid index; BP, blood pressure; EFW, estimated fetal
weight; PI, pulsatility index; SGA, small-for-gestational age; UA, umbilical artery.
The study was powered on the basis of the number
of cases needed to distinguish reliably good (80%) from
moderate (60%) sensitivity. Fifty-five cases were needed
for 90% power and 5% significance. This number was
met for all endpoints by recruiting 601 women, giving 78
cases of SGA<3rd birth-weight centile.
Statistical analysis
The predefined primary outcome (reference standard) was
delivery of a SGA infant< 3rd customized birth-weight
centile, calculated using version 6.7 of the GROW
calculator. SGA<10th centile and adverse perinatal
outcomes were considered as secondary outcomes.
PlGF centiles from a large low-risk antenatal pop-
ulation, adjusted for gestational age, were used27. An
abnormal result was defined as maternal PlGF concen-
tration< 5th centile, as this has been shown previously
to offer a combination of high sensitivity and acceptable
specificity for detecting PE and SGA, with a high negative
predictive value22. Levels of PlGF and three ultrasound
parameters (EFW< 10th centile; oligohydramnios, defined
as an amniotic fluid index< 5 cm; and umbilical artery
Doppler pulsatility index> 95th centile) were compared,
both in isolation and in combination, as predictors of
delivery of a SGA infant <3rd and < 10th customized
centiles. Gestational-age-adjusted centiles were calculated
for each observed value of umbilical artery Doppler
pulsatility index (UA-PI), based on a mean value of
0.405 – (0.0134 × gestational age (weeks)) and SD of
0.0794 for log10UA-PI28. Sensitivity, specificity and posi-
tive and negative predictive values (PPV and NPV, respec-
tively) were calculated with 95% CI. Receiver–operating
characteristics (ROC) curve areas were also calculated for
each individual parameter and their combinations, and in
a predefined subgroup of patients who delivered within
6 weeks of PlGF sampling. Fisher’s exact test was used
to compare the event rate in women with normal and
low PlGF measurements. Statistical analysis was carried
out in the Stata statistical package (version 11.2; Stata-
Corp, College Station, TX, USA). This study is reported
in accordance with the STAndards for the Report-
ing of Diagnostic accuracy studies (STARD) guidelines
(Table S1).
RESULTS
Six-hundred and one women presenting with a suspected
SGA fetus between 24 + 0 and 36 + 6 weeks’ gestation
were recruited across 11 sites between December 2011 and
July 2013. We recruited all women who were approached,
eligible and consented, but did not document women who
declined to participate. No outcome data were available
for two participants, and five women did not have PlGF
results generated by the test meter. A further two women
had no ultrasound data available at enrolment. After
exclusion of these nine cases, 592 women were included
in the subsequent analysis. Of these women, 192 delivered
a SGA infant with birth weight < 10th customized centile
and 78 had a birth weight < 3rd customized centile
(Figure 1).
Characteristics of participants at booking are given in
Table 1; higher rates of smoking were observed in women
who delivered a SGA infant. Table 2 displays baseline
characteristics at study enrolment. Details of maternal
and neonatal outcomes and final adjudicated maternal
diagnoses are shown in Table 3. The majority of women
(n = 555) experienced no maternal complications during
their pregnancy. Whilst the number of cases complicated
by PE was small (n = 16), most of these women delivered
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2015; 46: 182–190.
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Table 3 Characteristics of delivery and maternal and neonatal outcome in 592 women with singleton pregnancy presenting with reduced
symphysis–fundus height, according to birth-weight (BW) centile of infant
Characteristic
SGA<3rd centile
(n = 78)
SGA<10th centile
(n = 192)
BW ≥ 10th centile
(n = 400)
All women
(n = 592)
GA at delivery (weeks) 38.7 (37.1–40.1) 39.4 (38.0–40.4) 40.0 (39.0–40.9) 39.9 (38.9–40.7)
Maternal diagnosis
No new maternal disease in pregnancy 68 (86.3) 173 (89.2) 382 (95.5) 555 (93.4)
Pre-eclampsia 8 (10.0) 12 (6.2) 4 (0.99) 16 (2.7)
Gestational hypertension 0 (0) 0 (0) 8 (1.9) 8 (1.3)
Chronic hypertension 0 (0) 2 (1.0) 0 (0) 2 (0.3)
Other diagnosis 2 (2.5) 5 (2.6) 6 (1.5) 11 (1.8)
Maternal medication
Dexamethasone 5 (6.4) 7 (3.6) 4 (1.0) 11 (1.8)
Betamethasone 2 (2.6) 4 (2.1) 0 (0) 4 (0.7)
Methyldopa 2 (2.6) 2 (1.0) 0 (0) 2 (0.3)
Labetalol 6 (7.7) 9 (4.7) 2 (0.5) 11 (1.8)
Heparin 1 (1.3) 2 (1.0) 3 (0.8) 5 (0.8)
Nifedipine 1 (1.3) 2 (1.0) 1 (0.3) 3 (0.5)
Aspirin 3 (3.8) 4 (2.1) 8 (2.0) 12 (2.0)
Oral corticosteroids 0 (0) 3 (1.6) 2 (0.5) 5 (0.8)
Onset of labor
Spontaneous 24 (30.8) 99 (51.6) 300 (75.0) 399 (67.4)
Induced 41 (52.6) 67 (34.9) 66 (16.5) 133 (22.5)
Prelabor Cesarean section 13 (16.7) 26 (13.5) 34 (8.5) 60 (10.1)
Mode of delivery
Spontaneous 48 (61.5) 125 (65.1) 279 (69.8) 404 (68.2)
Assisted vaginal delivery 8 (10.3) 23 (12.0) 66 (16.5) 89 (15.0)
Cesarean section 22 (28.2) 44 (22.9) 55 (13.8) 99 (16.7)
Adverse maternal outcome* 5 (6.4) 9 (4.7) 10 (2.5) 19 (3.2)
Postpartum hemorrhage 2 (2.6) 5 (2.6) 7 (1.8) 12 (2.0)
Placental abruption 1 (1.3) 1 (0.5) 1 (0.3) 2 (0.3)
HELLP 0 (0) 0 (0) 1 (0.3) 1 (0.2)
Fetal outcome
Fetal death 0 (0) 0 (0) 1 (0.3) 1 (0.2)
Neonatal death 0 (0) 0 (0) 0 (0) 0 (0)
Birth weight (g) 2375 (2100–2610) 2660 (2360–2854) 3214 (3000–3470) 3050 (2740–3329)
Adverse perinatal outcome† 4 (5.1) 6 (3.1) 7 (1.8) 13 (2.2)
Data are given as median (interquartile range) or n (%). *Defined as presence of any of the following complications: maternal death,
eclampsia, stroke, cortical blindness or retinal detachment, hypertensive encephalopathy, systolic blood pressure ≥ 160 mmHg, myocardial
infarction, intubation (other than for Cesarean section), pulmonary edema, platelet count < 50 × 109/L (without transfusion), disseminated
intravascular coagulation, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, hepatic dysfunction (alanine transaminase
≥ 70 IU/L), hepatic hematoma or rupture, acute fatty liver of pregnancy, creatinine >150 μmol/L, renal dialysis, placental abruption, major
postpartum hemorrhage, major infection. †Defined as presence of any of the following complications: antepartum/intrapartum fetal or
neonatal death, neonatal unit admission for>48 h at term, intraventricular hemorrhage, periventricular leukomalacia, seizure, retinopathy
of prematurity, respiratory distress syndrome, bronchopulmonary dysplasia or necrotizing enterocolitis. GA, gestational age; HELLP,
hemolysis, elevated liver enzymes, low platelets; SGA, small-for-gestational age.
a SGA infant (n = 12). Of the 13 cases with adverse
perinatal outcome, there was one stillbirth, four cases of
respiratory distress syndrome and nine infants admitted
to the neonatal unit at term for> 48 h (one of whom had
respiratory distress syndrome).
Induction of labor and Cesarean section occurred more
frequently in SGA pregnancies compared with those with
birth weights appropriate-for-gestational age. Maternal
and perinatal adverse outcomes were reported in 3.2%
of women and in 2.2% of infants, respectively. Both
complications were higher in pregnancies with delivery of
a SGA infant (4.7% and 3.1%, respectively).
The median concentration of PlGF according to birth
weight was 94.5 (interquartile range (IQR), 36.3–324)
pg/mL for SGA< 3rd centile, 253 (IQR, 125–631) pg/mL
for SGA< 10th centile and 311 (IQR, 131–742) pg/mL
for birth weight ≥ 10th centile. The diagnostic accuracy of
PlGF and ultrasound parameters to determine SGA< 3rd
and< 10th centile are shown in Table 4, with EFW having
the highest sensitivity and NPV of all parameters assessed
alone. Addition of PlGF to current ultrasound parameters
utilized altered the test sensitivity from 58% to 69%
(NPV was unchanged at 93%) in determining SGA< 3rd
centile and from 47% to 57% (NPV increased from 77%
to 78%) in determining SGA< 10th centile. For women
presenting with reduced SFH before 37 weeks’ gestation
and in whom EFW was measured as ≥ 10th centile, low
PlGF concentrations at the time of scanning (< 5th centile)
would have detected an additional nine women with
subsequent SGA< 3rd centile. This difference in SGA< 3rd
centile between those with normal PlGF (5.9%; 23/390)
compared with those with low PlGF (20.5%; 9/44) was
significant (P = 0.002; Fisher’s exact test).
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2015; 46: 182–190.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
PlGF to predict SGA 187
Table 4 Diagnostic performance of placental growth factor (PlGF) and ultrasound parameters to predict small-for-gestational age
(SGA)<3rd and< 10th centiles in women presenting with reduced symphysis–fundus height (n = 592)
Biomarker/
clinical indicator
Sensitivity
(% (95% CI)) n/N
Specificity
(% (95% CI)) n/N
PPV
(% (95% CI)) n/N
NPV
(% (95% CI)) n/N
SGA<3rd centile
EFW< 10th centile 57.9 (46.0–69.1) 44/76 78.8 (75.0–82.3) 402/510 28.9 (21.9–36.8) 44/152 92.6 (89.8–94.9) 402/434
Oligohydramnios* 3.7 (0.5–12.7) 2/54 99.0 (97.0–99.8) 289/292 40.0 (5.3–85.3) 2/5 84.8 (80.5–88.4) 289/341
UA-PI> 95th centile 16.4 (8.2–28.1) 10/61 96.0 (93.5–97.7) 381/397 38.5 (20.2–59.4) 10/26 88.2 (84.8–91.1) 381/432
PlGF< 5th centile 37.2 (26.5–48.9) 29/78 88.7 (85.7–91.3) 456/514 33.3 (23.6–44.3) 29/87 90.3 (87.4–92.7) 456/505
Abnormal AFI or EFW 57.7 (43.2–71.3) 30/52 79.0 (73.9–83.6) 230/291 33.0 (23.5–43.6) 30/91 91.3 (87.1–94.4) 230/252
Abnormal PlGF or AFI
or EFW
69.2 (54.9–81.3) 36/52 72.2 (66.6–77.2) 210/291 30.8 (22.6–40.0) 36/117 92.9 (88.8–95.9) 210/226
SGA<10th centile
EFW< 10th centile 47.1 (39.7–54.5) 88/187 84.0 (80.0–87.4) 335/399 57.9 (49.6–65.8) 88/152 77.2 (72.9–81.1) 335/434
Oligohydramnios* 3.4 (0.9–8.5) 4/118 99.6 (97.6–100) 227/228 80.0 (28.4–99.5) 4/5 66.6 (61.3–71.6) 227/341
UA-PI> 95th centile 8.2 (4.3–13.8) 12/147 95.5 (92.6–97.5) 297/311 46.2 (26.6–66.6) 12/26 68.8 (64.1–73.1) 297/432
PlGF< 5th centile 24.5 (18.6–31.2) 47/192 90.0 (86.6–92.8) 360/400 54.0 (43.0–64.8) 47/87 71.3 (67.1–75.2) 360/505
Abnormal AFI or EFW 48.7 (39.3–58.2) 56/115 84.6 (79.3–89.1) 193/228 61.5 (50.8– 71.6) 56/91 76.6 (70.9–81.7) 193/252
Abnormal PlGF or AFI
or EFW
57.4 (47.8–66.6) 66/115 77.6 (71.7–82.9) 177/228 56.4 (46.9–65.6) 66/117 78.3 (72.4–83.5) 177/226
Amniotic fluid index (AFI), estimated fetal weight (EFW) and umbilical artery (UA) Doppler were not recorded in all subjects. *AFI < 5 cm.
NPV, negative predictive value; PI, pulsatility index; PPV, positive predictive value.
In the whole cohort, the ROC area was greater for
EFW<10th centile (0.79 (95% CI, 0.74–0.84)) than
for low PlGF levels (0.70 (95% CI, 0.63–0.77)) for
the prediction of SGA< 3rd centile; when used in
combination, this increased to 0.82 (95% CI, 0.77–0.86)
(Figure 2a). In a planned subgroup analysis of 267
women in whom delivery occurred within 6 weeks
of PlGF sampling (Table S2), ROC areas were 0.76
(95% CI, 0.69–0.84), 0.74 (95% CI, 0.66–0.83) and
0.81 (95% CI, 0.72–0.88) for EFW<10th centile, low
PlGF and a combination of both parameters, respectively
(Figure 2b).
The outcomes of 16 participants with a very low
PlGF concentration (<12 pg/mL; below the level of assay
detection) at enrolment are shown in Table S3. Seven
women had hypertensive complications of pregnancy
(7/16 (44%) vs 17/576 (3%) in the rest of the cohort) and
11 women delivered a SGA infant with birth weight< 10th
customized centile.
There were no adverse events associated with blood
sampling for PlGF measurement.
DISCUSSION
In this multicenter prospective cohort study of women
presenting with reduced SFH, ultrasound parameters uti-
lized currently, including EFW< 10th centile, had modest
test performance for predicting delivery of a SGA infant.
Maternal PlGF measurement performed no better than
these ultrasound parameters and provided only minimal
increments in overall test performance when used in com-
bination. This contrasts with the findings of our previous
study, assessing the diagnostic accuracy of PlGF levels
in women with suspected PE, which reported excellent
performance (sensitivity, 93%; NPV, 96%) in predicting
SGA in women presenting at< 35 weeks’ gestation22.
There are several possible explanations for the
differences observed in these studies. The majority
of women recruited into this study had no maternal
complications in pregnancy (555/592; 93%) and only 24
(4%) had a new hypertensive disorder. This contrasts
with our previous high-risk cohort, in which 61%
of women enrolled at< 35 weeks’ gestation developed
PE22. Differing pathological processes may occur in the
placentae of pregnancies complicated by hypertensive
disease, particularly if early onset, and in those who
remain normotensive but deliver a SGA infant29. The
gestational age at delivery of SGA infants< 3rd centile
in this study was 38.7 weeks (with 5% adverse perinatal
outcome), compared with 33.8 weeks (with 39% adverse
perinatal outcome) in the previous study, emphasizing the
probably different placental pathophysiology. The median
gestational age at PlGF sampling and at delivery was 34
weeks and 40 weeks, respectively. PlGF appears to have
limited clinical utility in women presenting with reduced
SFH late in pregnancy and delivering near term. This
may reflect convergence of PlGF measurements between
normal and pathological pregnancies with advancing
gestation27 and the heterogeneous etiology of SGA, even
when categorized as birth weight< 3rd customized centile.
PlGF is an angiogenic factor produced principally by
trophoblasts. Low maternal plasma PlGF concentrations
reflect placental dysfunction and have been described
in early-onset PE and SGA, associated with abnormal
placental pathology21.
It is particularly notable that adverse perinatal outcome
occurred infrequently (2.2%) in this study; this makes
conclusions regarding the ability of PlGF to determine
adverse outcomes impossible. The single case of stillbirth
had a normal PlGF concentration and was not SGA;
therefore, placental insufficiency is an unlikely etiology.
The neonatal characteristics in this study (Table 3)
are markedly different from those described in the
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2015; 46: 182–190.
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Figure 2 Receiver–operating characteristics curves for low
placental growth factor (PlGF) ( ), low estimated fetal weight
(EFW)< 10th centile ( ) and a combination of these parameters
( ) to predict delivery of a small-for-gestational-age infant
with birth weight< 3rd centile in: (a) all women (n = 592); and
(b) women who delivered within 6 weeks of PlGF sampling
(n = 267). (a) Area under the curve (AUC) for: low PlGF = 0.70
(95% CI, 0.63–0.77), EFW < 10th centile = 0.79 (95% CI,
0.74–0.84) and their combination = 0.82 (95% CI, 0.77–0.86).
(b) AUC for low PIGF = 0.74 (95% CI, 0.66–0.83), low EFW
< 10th centile = 0.76 (95% CI, 0.69–0.84) and their combination
= 0.81 (95% CI, 0.72–0.88).
previous PlGF study, in which nine (2.1%) cases of
stillbirth/neonatal death were reported, with adverse
perinatal outcome in 19%22.
This is the largest reported prospective study evaluating
the ability of third-trimester PlGF concentration to predict
delivery of a SGA infant in women presenting with
reduced SFH. Recruitment from 11 centers across the UK
and Canada provided a diverse ethnic and geographical
population. PlGF was measured at the recruiting site, as
would occur if adopted into clinical practice. The PlGF
results were concealed until assignment of a final maternal
diagnosis at study completion. The study entry criterion,
reduced SFH, was selected for clinical relevance, reflecting
current referral practice in the UK. A primary endpoint of
delivering an infant< 3rd customized birth-weight centile
was selected as it includes fewer constitutionally small
infants and has a stronger association with perinatal
mortality7.
This study included only PlGF measurement at
study enrolment. Serial measurements to assess whether
longitudinal changes in PlGF correlate with evolving
placental dysfunction could be informative. When routine
antenatal third-trimester ultrasound in low-risk women
is performed, the findings of this study may be less
applicable.
A systematic review evaluating biomarkers for pre-
dicting FGR identified 13 studies that reported test
performance for PlGF in predicting delivery of a SGA
infant20. In a subgroup of studies recruiting women after
20 weeks’ gestation, the pooled PlGF sensitivity (at var-
ious thresholds) for prediction of intrauterine growth
restriction (using differing definitions) was 49% (95% CI,
44–53%). Comparisons were difficult because of hetero-
geneity between studies. The majority were case–control
studies, with only two cohort studies recruiting women
over 20 weeks’ gestation. Of these, one was in an abnor-
mal population (abnormal uterine artery Doppler wave-
forms at 20 weeks’ gestation), whilst, in the other, delivery
of a SGA infant was a secondary endpoint. No cohort
studies recruiting in the third trimester were evaluated. A
recent study evaluated maternal PlGF concentration at a
fixed time point (30–34 weeks’ gestation) and reported
increased adjusted odds ratio for PlGF combined with
other angiogenic factors in the prediction of delivering a
SGA infant, but did not provide test performance statistics
to enable comparison30.
The capabilities of current standard ultrasound param-
eters to determine delivery of a SGA infant must also
be considered. A large study published a sensitivity of
27% for SFH measurement to predict delivery of a SGA
infant10. Reported test performance of EFW< 10th centile
to predict pregnancies delivering a SGA infant (sensitiv-
ity, 21–46%; NPV, 90–94%)14,17 are similar to those
published in this cohort (sensitivity, 47%; NPV, 77%).
Three Cochrane systematic reviews evaluating SFH31,
routine ultrasound measurement (including EFW)18 and
fetal and umbilical artery Doppler assessment in low-risk
pregnancy32 concluded that none of these techniques
reduced adverse perinatal outcome. Use of customized
SFH charts and EFW centiles, which adjust for maternal
characteristics, may improve SGA detection33, prediction
of delivering a SGA infant13,34 and adverse outcome,
including stillbirth35 and neonatal death36. Implementa-
tion of customized charts in conjunction with accredited
training is associated with a reduction in stillbirth rates
in areas of high uptake37 but has not been validated in a
randomized control trial.
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2015; 46: 182–190.
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A systematic review and meta-analysis assessing
amniotic fluid index reported a strong correlation between
oligohydramnios and delivery of a SGA infant (birth
weight< 10th centile) and mortality, but the predictive
accuracy for perinatal outcome was poor38. This agrees
with our findings of high specificity for delivery of a SGA
infant (99.6% (95% CI, 97.6–100%)) but low sensitivity
(3.4% (95% CI, 0.9–8.5%)), limiting clinical application
without incorporating other clinical factors. Novel
ultrasound parameters, such as the cerebroplacental ratio,
have been reported as potentially useful in predicting
neonatal status, and validation is awaited39.
We previously suggested PlGF measurement as a useful
adjunct to current clinical practice in women with
suspected preterm PE, but the findings from this study
cannot support its use in women with reduced SFH. Whilst
EFW<10th centile has only modest test performance for
prediction of SGA, addition of PlGF measurement does
not improve test performance significantly. This study
highlights the need for caution when generalizing findings
from one population to another and alerts against the
overenthusiastic adoption of novel biomarkers without
appropriate evaluation.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Table S1 STARD checklist for reporting of studies of diagnostic accuracy
Table S2 Diagnostic performance for placental growth factor (PlGF) and ultrasound parameters to predict
small-for-gestational age (SGA)<3rd centile when PlGF was sampled within 6 weeks of delivery (n = 267) in
women with reduced symphysis–fundus height
Table S3 Maternal outcome in 16 women with very low placental growth factor levels (<12 pg/mL) at
sampling
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